Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Jan;34(1):e14652.
doi: 10.1111/dth.14652. Epub 2020 Dec 19.

The impact of COVID-19 pandemic on the management of patients with chronic urticaria: An observational two-center study from Turkey

Yasemin Erdem  1 , Algün Polat Ekinci  2 , Ilknur Kivanc Altunay  1 , Onur Sivaz  1 , Sena Inal  1 , Mehmet Onur Gokalp  2 , Gizem Pehlivan  2 , Esen Özkaya  2
Affiliations

The impact of COVID-19 pandemic on the management of patients with chronic urticaria: An observational two-center study from Turkey

Yasemin Erdem et al. Dermatol Ther. 2021 Jan.

Abstract

The Coronavirus Disease 2019 (COVID-19) outbreak significantly affected the clinical practice in hospitals and the management of many diseases. The aim of this study was to evaluate the effect of pandemic-related factors on the severity and course of chronic urticaria (CU). A total of 194 CU patients who were on regular follow-up, were enrolled in the study. The disease activity was assessed by means of the weekly urticaria activity score (UAS7) and urticaria control test (UCT). Patients were divided into two subgroups according to their disease aggravation as "aggravated" and "non-aggravated". Two groups were compared in terms of demographic, clinical, COVID-19-associated parameters, and parameters related with the effect of COVID-19 pandemic on CU management. The omalizumab use was statistically higher (P = .017), and the systemic corticosteroid use was statistically lower (P = .025) in the "aggravated" group. Adherence to quarantine was significantly lower in the "aggravated" group (P = .027). 173 patients (89.2%) were unable to contact a dermatologist during the pandemic. Among 186 patients who received treatment for CU before the pandemic, 48 (25.8%) did not continue the existing treatment during the pandemic. CU aggravated in one patient with COVID-19 and remained stable in the other. This study showed that CU patients, especially those on omalizumab therapy, had difficulties in attending medical care and even in the maintenance of their existing therapies during the pandemic. Creating novel follow-up and treatment models as well as the increased use of teledermatology might be beneficial in the management of this life-disturbing condition.

Keywords: COVID-19; UAS7; UCT; chronic urticaria; management; omalizumab; pandemic.

PubMed Disclaimer

Conflict of interest statement

The authors declare no potential conflict of interest.

Comment in

References

    1. WHO (2020) Considerations in adjusting public health and social measures in the context of COVID‐19 (Interim Guidance, 16 April 2020) (WHO 2020). https://www.who.int/publications-detail/considerations-in-adjusting-publ.... Accessed November 4, 2020.
    1. Zuberbier T, Aberer W, Asero R, et al. The EAACI/GA2LEN/EDF/WAO guideline for the definition, classification, diagnosis and management of urticaria. Allergy. 2018;73:1393‐1414. - PubMed
    1. Bernstein JA, Lang DM, Khan DA, et al. The diagnosis and management of acute and chronic urticaria: 2014 update. J Allergy Clin Immunol. 2014;133:1270‐1277. - PubMed
    1. Özkaya E, Babuna Kobaner G, Yılmaz Z, Kutlay A. Doxepin in difficult‐to‐treat chronic urticaria: a retrospective, cross‐sectional study from Turkey. Dermatol Ther. 2019;32:e12993. - PubMed
    1. Lee JH, Lee Y, Lee SY, et al. Management of allergic patients during the COVID‐19 pandemic in Asia. Allergy Asthma Immunol Res. 2020;12:783‐791. - PMC - PubMed